Abstract
Statins and type 2 diabetes: genetic studies on target
Highlights
10 Cuchel M, Meagher EA, du Toit Theron H, et al Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
In The Lancet, Daniel Swerdlow and colleagues[1] used an updated meta-analysis of trials to investigate whether or not statins increased the risk of type 2 diabetes, and a genetic approach to address how statins might increase the risk of the disorder
Using data from 20 randomised controlled trials, they confirm findings from previous reports that statin treatment increased the risk of incident type 2 diabetes, with an odds ratio (OR) of 1·12 versus controls
Summary
10 Cuchel M, Meagher EA, du Toit Theron H, et al Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. In The Lancet, Daniel Swerdlow and colleagues[1] used an updated meta-analysis of trials to investigate whether or not statins increased the risk of type 2 diabetes, and a genetic approach to address how statins might increase the risk of the disorder.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
